| Species |
Human |
| Protein Construction |
IL-6 (Val30-Met212)
Accession # P05231 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 0.05EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-6, Human at 2μg/ml (100μl/Well) on the plate can bind Human IL6 R alpha, hFc Tag. Test result was comparable to standard batch.
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.1 0.5 ng/mL. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
20.8 kDa |
| Apparent Molecular Weight |
The protein has a predicted 20.8 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. |
| Synonyms |
IFN-beta-2; IL6; IL-6; BSF-2; CDF; MGI-2A; Interleukin-6; HSF; IFNB2; HGF;IFN-β-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
